AppMed
Understanding menopause, perimenopause and hormone therapy — clear, current information grounded in Canadian clinical guidelines.
Section 1
The information presented on this page is provided by AppMed for general educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Always seek the guidance of your physician, nurse practitioner, or other qualified health care provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay seeking it because of something you have read here.
Content is summarized from publicly available materials of the Society of Obstetricians and Gynaecologists of Canada (SOGC), the Canadian Menopause Society, the Menopause Foundation of Canada, the Heart and Stroke Foundation of Canada, the Canadian Cancer Society, and the Government of Canada. Recommendations evolve — please refer to the linked resources for current clinical guidance.
Section 3
Perimenopause is the transitional phase that leads up to menopause. It typically begins in a woman's 40s — though symptoms may appear in the 30s — and lasts on average 2 to 10 years before menopause itself.1,2
During this time, levels of estrogen and progesterone rise and fall unpredictably, often producing a wide range of physical and emotional symptoms.1
Common signs include:
Diagnosis is generally made on the basis of symptoms and menstrual changes; routine hormone testing (FSH, estradiol) is unreliable during this phase because hormone levels fluctuate widely.2
Menopause is reached when a woman has gone 12 consecutive months without a menstrual period, marking the natural end of reproductive years.3,4
The average age of menopause in Canada is 51 years.3 Menopause may also occur earlier — naturally, surgically (after removal of the ovaries), or as a consequence of medical treatments such as chemotherapy or pelvic radiation.1
Stages recognized in Canadian clinical guidance:
Early menopause is defined as menopause before age 45, and premature ovarian insufficiency (POI) as menopause before age 40. Approximately 1 in 100 Canadian women experience menopause before 40.5
Menopausal Hormone Therapy (MHT) — historically called Hormone Replacement Therapy (HRT) — uses estrogen, with or without a progestogen, to relieve symptoms of menopause.7
According to the Society of Obstetricians and Gynaecologists of Canada (SOGC) Guideline No. 422a (2021), MHT is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and can be safely initiated in women without contraindications who are under 60 years of age or within 10 years of menopause.7,8
Forms available in Canada:
Reported benefits for appropriate candidates include relief of hot flashes and night sweats, improved sleep and mood, reduction of genitourinary symptoms, and prevention of bone loss.7,9
Potential risks may include a small increase in risk of breast cancer (with combined therapy used long-term), venous thromboembolism, stroke, and gallbladder disease. Risk varies with age, type of hormone, dose, route, and individual health profile.9,10
Discuss your personal benefit–risk profile with your health care provider before starting, modifying, or stopping any hormone therapy.
Section 4
The average age of natural menopause in Canada is 51 years, with most women reaching it between ages 45 and 55. About 1 in 100 women experience menopause before age 40 (premature ovarian insufficiency).3,5
Perimenopause typically lasts 2 to 10 years, with an average of 4 to 8 years. In some women it can extend longer. It ends 12 months after the final menstrual period.1,2
Hot flashes and night sweats (vasomotor symptoms) affect up to 80% of women. Other common symptoms include sleep disruption, mood changes, brain fog, vaginal dryness, joint aches, and fatigue. More than 30 distinct symptoms have been associated with the menopause transition.2,4
For most healthy women under 60 or within 10 years of menopause who do not have contraindications, the benefits of MHT for managing bothersome symptoms generally outweigh the risks, according to the SOGC and the Menopause Society. Risk profiles are individual and should be reviewed with your provider.7,9
MHT is generally not recommended for women with a history of breast cancer, estrogen-sensitive cancers, unexplained vaginal bleeding, active liver disease, prior venous thromboembolism (blood clots), stroke, or untreated hypertension. A full personal and family history is essential.9,10
Yes. Health Canada has approved fezolinetant (a neurokinin-3 receptor antagonist) for vasomotor symptoms. Other options used in Canada (often off-label) include certain SSRIs and SNRIs, gabapentin, and oxybutynin. Lifestyle changes — regular exercise, reduced alcohol and caffeine, layered clothing, stress management — may also help.2
Speak to your provider if you are under 40 with menopausal symptoms or irregular periods, have heavy bleeding or bleeding between periods or after sex, or if your symptoms are interfering with your sleep, work, relationships, or quality of life.3
Yes. Estrogen has a protective effect on bones and the cardiovascular system. After menopause, the risk of osteoporosis, heart disease and stroke increases. The Heart and Stroke Foundation of Canada recommends discussing cardiovascular risk assessment with your provider during midlife.6
Section 5
Curated links to authoritative Canadian organizations for further reading and ongoing support.
References
Last reviewed: April 2026. Content is provided for educational purposes by AppMed and is not a substitute for individualized medical advice. Please consult a qualified Canadian health care professional for guidance specific to your situation.
AppMed · Women’s Health Module
© AppMed. Educational content based on Canadian clinical guidelines.